Gensight Biologics SA Stock
Your prediction
Gensight Biologics SA Stock
We can see a decrease in the price for Gensight Biologics SA. Compared to yesterday it has lost -€0.003 (-2.870%).
For the coming years our community has positive and negative things to say abot the Gensight Biologics SA stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Gensight Biologics SA in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Gensight Biologics SA vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Gensight Biologics SA | -2.870% | -7.591% | -19.912% | -70.066% | -65.805% | -97.465% | -98.539% |
| Protara Therapeutics Inc. | 4.170% | 6.383% | 12.108% | -13.043% | -2.913% | 77.305% | -71.910% |
| India Globalization Capital | -3.520% | 14.167% | -9.868% | -22.159% | -18.452% | -18.136% | -79.865% |
| BioInvent International AB | 0.000% | -1.961% | -8.925% | -28.161% | -24.699% | -22.958% | -35.317% |
Comments
News
GenSight Biologics Announces Publication on Predictors of Final Visual Outcome in Patients Treated with LUMEVOQ® Gene Therapy
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
GenSight Biologics Reports Cash Position as of June 30, 2025
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal